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Purpose or Objective: The aim of this prospective study is 
the comparison of perfusion parameters changes (∆CTPp) 
before and after radio-chemotherapy (RCT) and their 
correlation with maximum standard uptake values variations 
(∆SUV max) among patients (pts) with head and neck tumor 
(HNT), in order to evaluate the prognostic value of perfusion 
CT parameters (CTPp) in predicting response to RCT. 
 
Material and Methods: We enrolled pts with intermediate 
and advanced stage of HNT (stage III-IV), candidated to RCT 
with curative intent. All pts underwent to a pretreatment 
diagnostic and staging workup including perfusion CT (CTP) 
and FDG-PET/CT total body. Pts also perform a CTP 3 weeks 
after the end of RCT (CTP3w) and both CTP and PET/CT 3 
months after the end of RCT (CTP3m and PET/CT 
repectively). We analised variations of following CTPp: Blood 
Flow (BF), Blood Volume (BV), Mean Transit Time (MTT) and 
Permeability-surface product (PS). All RCT treatments were 
performed using intensity modulated radiotherapy technique 
with simultaneous integrated boost. Prescribed doses were 66 
Gy at 2.2 Gy per fraction to high risk volume PTV and 60-54 
Gy at 2.0- 1.8 Gy per fraction respectively to intermediate 
(optional) and low risk PTVs, delivered in 30 daily fractions. 
Concurrent weekly Cisplatin 40 mg/ m2 or Cisplatin 100 
mg/m2 day 1, 22 an 43 was offered to all pts. 
 
Results: From July 2012 to July 2015 25 pts affected by stage 
III/IV HNT candidate to RCT were enrolled in our study. FDG-
PET/CT 3 months after the end of RCT showed a complete 
metabolic response in 16 pts (64%), a partial metabolic 
response in 7 pts (28%), a stable metabolic disease in 1 pts 
and progression metabolic disease in 1 pts (according PERCIS 
criteria). A significant reduction of all CTPp was observed 
from baseline CTP to CTP3w, except for MTT that did not 
show a significant variation (p=0,722). The analysis of 
differences between baseline CTP and CTP3m showed a 
significant reduction of all CTPp (p<0,001), including MTT 
(p=0,001). PET/CT response resulted statistically correlated 
to reduction of all CTPp both at 3 weeks and at 3 months 
after the end of RCT, except for MTT (p=0,998 and 0,692). At 
the multivariate analysis the PS was the only parameter that 
maintain a statistical significance at CTP3m (p=0,037) with a 
significant trend also at CTP3w(p=0,099). 
 
Conclusion: The induced damage on the intratumor 
microvascularization and low resistance flow of neoplastic 
vessels, explain the decrease of BV and BF whereas the 
reduction of neoangiogenesis phenomenon could explain the 
observed decrease of PS.Despite poor sample size, our 
preliminary results seem to be promising for a potential role 
of CTP to predict tumor response. PS seems the most 
valuable to predict the FDG-PET/CT tumor response. Due to 
the small sample size and short follow up, our results need to 
be confirmed in other series. Both funcional and 
morphological datas of the CTP can be usefull in order to 
reduce as much as possible the rate of false positive. 
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Purpose or Objective: The goal of this study is was to 
evaluate the results of treatment of T1N0M0 glottic cancer 
with irradiation, with emphasis on the influence of time from 
diagnosis to the beginning of radiation therapy. 
 
Material and Methods: We performed the retrospective 
analysis of the group of 539 patients with T1N0M0 glottic 
cancer, treated with radiation therapy in one institute 
between 1977 and 2004. In 481 cases (89%) the tumor was 
limited to single vocal cord and in the remaining 58 involved 
both of them. Anterior commisure involvement was observed 
in 173 (32%) of the patients. According to the radiotherapy 
technique and fractionation scheldule, we have divided 
patients into three separate groups: I - two oblique fields, TD 
60 Gy/24 - 277 patients (51%); II - two opposite fields, TD 60 
Gy/30 - 160 (31%); III - one lateral photon-electron beam, TD 
60 Gy/30 - 102 (19%). The average time from laryngeal biopsy 
to the beginning of radiotherapy was 56 days (range: 3 -145 
days).  
 
Results: The 5-year OS and 10-year OS were 84% and 69%, 5- 
and 10-year DFS were 90% and 88%, and the 5- and 10-year LC 
rates were 89% and 87%, respectively. One- dimensional 
analysis revealed following prognostic factors for LC and DFS: 
tobbaco smoking, radiotherapy technique, and the anterior 
commisure involvement. The 5- and 10-year LC rates in the 
group of patients smoking less than 20 cigarettes a day were 
90% and 87%, compared to 76% and 70%, respectively, in the 
group smoking more than 20 cigarettes a day (p=0,01). 
Considering the RT technique, the lowest 5- and 10-year LC 
rates were observed in the group treated with opposite 
beams (80% and 78%, respectively), and the highest when the 
oblique fields were used - 91% and 88%, respectively 
(p=0,002). The tumor involvement of the anterior commisure 
decreased 5-year LC by 15% (92 to 77%), and 10- year LC rate 
by 19% (89 to 70%, respectively, p=0,000). The waiting time 
for the beginning of RT longer than 30 days from the biopsy 
was statistically significant poor prognostic factor for DFS and 
LC. 5- and 10- year LC rates in the group of patients who 
started RT during the period of 30 days from the biopsy were 
92% and 90%, respectively, and in the group which started 
treatment after that time, these LC rates were 84% and 82%, 
respectively (p=0,01).  
 
Conclusion: Radiation therapy is efficient method of 
treatment the T1N0M0 glottic cancer. Prolonged time of 
waiting for the beginning of RT decreases the LC and DFS 
rates  
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Purpose or Objective: To evaluate the overall response rate 
and access the toxicity for patients with locally advanced 
squamous cell carcinoma of head and neck (HNSCC) receiving 
a novative docetaxel-based outpatient neoadjuvant 
chemotherapy regimen. 
 
Material and Methods: The inclusion criteria for this 
prospective study are (1)Age≧20 years old (2) Histologically 
proven squamous cell carcinoma of the oral cavity, 
oropharynx, hypopharynx, or larynx (3)Stage III or stage IVA 
or IVB without distant metastasis, (4) No prior chemotherapy 
given for HNSCC (5) Physician’s intention to treat with 
docetaxel- baed induction therapy (6) Patients’ informed 
consent will be obtained. Tumor response for induction 
chemotherapy will be evaluated in patient with measurable 
disease according to institutional guidance. The induction 
chemotherapy regimen is a novative outpatient regimen. This 
regimen consists of cisplatin 60mg/m2 on day 1, docetaxel 50 
mg/m2 on day 8, 5-Fu 2500 mg/m2 and leucovorin 250 
mg/m2 on day 15, and methotrexate 30 mg/m2 and 
epirubicin 30 mg/m2 on day 21, cycles will be repeated for a 
total 3 to 4 cycles followed by surgery or radiotherapy. 
Responses rate will be reported using Response Evaluation 
Criteria In Solid Tumors (RECIST) criteria in patients with at 
least one measurable lesion. Toxicity will be recoreded using 
the NCI-CTC v.4.03. 
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Results: From September 2011 to December 2013, 80 
patients were enrolled and two patients withdrew consent, 
finally 78 patients included for analysis. There were 73 male 
and 5 female. There were 96.2% of them had 0-1 WHO ECOG. 
For the primary site, 23(29.5%) patients were oral cavity, 26 
(33.3%) patients were oropharynx, 24(30.8%) patients were 
hypopharynx, and 5 (6.4%) patients were larynx. Treatment 
compliance was well. There were 92.3% patients completed 
planned schedule. After the induction chemotherapy, the 
overall response rate were 92.3%, which included 37.2% 
complete response and 55.1% partial response, respectively. 
Only 2(2.6%) patients had stable disease and 1(1.3%) patient 
had progression disease. The response rate of oral cavity, 
oropharynx, hypopharynx, and larynx were 82.6%, 92.3%, 
100%, 100%, respectively. There were 47.4% grade 3 or 4 
neutropenia and 20.5% grade 3 anemia. Only 6 severe adverse 
event were report, including 4 febrile neutropenia with 
sepsis, one osteomyelitis, and one massive bleeding. 
 
Conclusion: This outpatient docetaxel-based neoadjuvant 
chemotherapy regimen is a effective regimen in locally 
advanced squamous cell carcinoma of head and neck. 
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Purpose or Objective: The goal of this study is was to 
evaluate the results of treatment of T1N0M0 glottic cancer 
with irradiation, with emphasis on the influence of time from 
diagnosis to the beginning of radiation therapy. 
 
Material and Methods: We performed the retrospective 
analysis of the group of 539 patients with T1N0M0 glottic 
cancer, treated with radiation therapy in the Center of 
Oncology in Cracow between years 1977 and 2004. In 481 
cases (89%) the tumor was limited to single vocal cord and in 
the remaining 58 involved both of them. Anterior commisure 
involvement was observed in 173 (32%) of the patients. 
According to the radiotherapy technique and fractionation 
scheldule, we have divided patients into three separate 
groups: I - two oblique fields, TD 60 Gy/24 - 277 patients 
(51%); II - two opposite fields, TD 60 Gy/30 - 160 (31%); III - 
one lateral photon-electron beam, TD 60 Gy/30 - 102 (19%). 
The average time from laryngeal biopsy to the beginning of 
radiotherapy was 56 days (range: 3 -145 days). The overall 
survival (OS) and disease- free survival (DFS) were calculated 
using the Kaplan - Meier method. Log - rank test was used to 
calculate differences between each groups, and the 
independent prognostic factors were selected by the Cox 
multiparameter analysis. 
 
Results: The 5-year OS and 10-year OS were 84% and 69%, 5- 
and 10-year DFS were 90% and 88%, and the 5- and 10-year LC 
rates were 89% and 87%, respectively. One- dimensional 
analysis revealed following prognostic factors for LC and DFS: 
tobbaco smoking, radiotherapy technique, and the anterior 
commisure involvement. The 5- and 10-year LC rates in the 
group of patients smoking less than 20 cigarettes a day were 
90% and 87%, compared to 76% and 70%, respectively, in the 
group smoking more than 20 cigarettes a day (p=0,01). 
Considering the RT technique, the lowest 5- and 10-year LC 
rates were observed in the group treated with opposite 
beams (80% and 78%, respectively), and the highest when the 
oblique fields were used - 91% and 88%, respectively 
(p=0,002). The tumor involvement of the anterior commisure 
decreased 5-year LC by 15% (92 to 77%), and 10- year LC rate 
by 19% (89 to 70%, respectively, p=0,000). The waiting time 
for the beginning of RT longer than 30 days from the biopsy 
was statistically significant poor prognostic factor for DFS and 
LC. 5- and 10- year LC rates in the group of patients who 
started RT during the period of 30 days from the biopsy were 
92% and 90%, respectively, and in the group which started 
treatment after that time, these LC rates were 84% and 82%, 
respectively (p=0,01). Tumor interior commisure involvement 
was proven to be an independent prognostic factor affecting 
DFS and LC. 
 
Conclusion:  
1. Radiation therapy is efficient method of treatment the 
T1N0M0 glottic cancer 
2. Prolonged time of waiting for the beginning of RT 
decreases the LC and DFS rates 
3. The tumor involvement of anterior laryngeal commisure 
proved to be an independent adverse prognostic factor for LC 
and DFS 
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Purpose or Objective: The aim of the present study is to 
analyze clinical outcomes and toxicity in patients with 
locoregionally advanced head and neck carcinoma treated 
with concurrent hyperfractionated radiotherapy with 
Cetuximab and Carboplatin. 
 
Material and Methods: Forty-one patients (8 cases ST.III and 
33 cases ST.IV) were prospectively included in this study from 
September 2009 to November 2014. Radiotherapy consisted 
in hyperfractionated radiotherapy: 1.15-1.20 Gy/fraction, 
BID, 5 days/week during 7 weeks. The average dose 
administered was 80.2 Gy (79.2-80.5). Carboplatin was 
administered 5 mg/m2 before each fraction of radiotherapy. 
Cetuximab was administered 400 mg/m2 one week before 
hyperfractionated radiotherapy and then 250 mg/m2 weekly 
while radiotherapy. Seven patients were not evaluable for 
response (in 3 patients, Capecitabine was added to the 
treatment; in 1 patient nodal metastases came from a 
papillary thyroid carcinoma; 3 patients were not evaluable 
for response because 2 patients died within 30 days after 
treatment and 1 patient has not enough follow-up to be 
evaluated for response). 
 
Results: All but 2 of the 34 evaluable patients showed 
objective response (19 complete responses). The local 
relapse-free survival, cause specific survival, and overall 
survival was 58.7%, 57%, 49% at 5 years, respectively. Severe 
(GradeII/III) acneiform rash resulted predictive of Clinical 
Response (p=0,005), Local relapse (p=0,008), distant 
metastases (p=0,012) and tumour related dead free survival 
(p<0,0001). Severe (Grade III) acute cutaneous and mucosal 
toxicity was present in almost 60% of the cases.  
 
Conclusion: This protocol induces a high rate of clinical 
responses and excellent survival figures in patients 
developing an strong immune response after combined radio-
chemoimmunotherapy.  
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